Hubbry Logo
ZiprasidoneZiprasidoneMain
Open search
Ziprasidone
Community hub
Ziprasidone
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Ziprasidone
Ziprasidone
Ziprasidone
View on Wikipedia
from Wikipedia

Ziprasidone
Clinical data
Trade namesGeodon, others
AHFS/Drugs.comMonograph
MedlinePlusa699062
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth, intramuscular injection (IM)
Drug classAtypical antipsychotic
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability60% (oral)[3]
100% (IM)
MetabolismLiver (aldehyde reductase)
Elimination half-life7 to 10 hours[4]
ExcretionUrine and feces
Identifiers
  • 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.106.954 Edit this at Wikidata
Chemical and physical data
FormulaC21H21ClN4OS
Molar mass412.94 g·mol−1
3D model (JSmol)
  • O=C1Cc2c(N1)cc(Cl)c(c2)CCN3CCN(CC3)c4nsc5ccccc45
  • InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27) checkY
  • Key:MVWVFYHBGMAFLY-UHFFFAOYSA-N checkY
  (verify)
3D-animation of a ziprasidone molecule.
Ziprasidon Krka brand medicine.
Wikimedia Commons has media related to Ziprasidone.

Ziprasidone, sold under the brand name Geodon among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder.[5] It may be used by mouth and by injection into a muscle (IM).[5] The intramuscular form may be used for acute agitation in people with schizophrenia.[5]

Common side effects include tremors, tics, dizziness, dry mouth, restlessness, nausea, and mild sedation.[6][7] Although it can also cause weight gain, the risk is much lower than for other atypical antipsychotics.[8] How it works is not entirely clear but is believed to involve effects on serotonin and dopamine in the brain.[5]

Ziprasidone was approved for medical use in the United States in 2001.[5] The pills are made up of the hydrochloride salt, ziprasidone hydrochloride. The intramuscular form is the mesylate, ziprasidone mesylate trihydrate, and is provided as a lyophilized powder. In 2020, it was the 282nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.[9][10]

Medical uses

[edit]

Ziprasidone is approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia as well as acute mania and mixed states associated with bipolar disorder. Its intramuscular injection form is approved for acute agitation in schizophrenic patients for whom treatment with just ziprasidone is appropriate.[11]

In a 2013 study in a comparison of 15 antipsychotic drugs in effectiveness in treating schizophrenic symptoms, ziprasidone demonstrated mild-standard effectiveness. Ziprasidone was 15% more effective than lurasidone and iloperidone, approximately as effective as chlorpromazine and asenapine, and 9–13% less effective than haloperidol, quetiapine, and aripiprazole.[12] Ziprasidone is effective in the treatment of schizophrenia, though evidence from the CATIE trials suggests it is less effective than olanzapine, and equally as effective compared to quetiapine. There are higher discontinuation rates for lower doses of ziprasidone, which are also less effective than higher doses.[13]

Adverse effects

[edit]

Ziprasidone (and all other second generation antipsychotics (SGAs)) received a boxed warning in the US due to increased mortality in elderly people with dementia-related psychosis.[2]

Sleepiness and headache are very common adverse effects (>10%).[6][7]

Common adverse effects (1–10%), include producing too much saliva or having dry mouth, runny nose, respiratory disorders or coughing, nausea and vomiting, stomach aches, constipation or diarrhea, loss of appetite, weight gain (but the smallest risk for weight gain compared to other antipsychotics[8]), rashes, fast heart beats, blood pressure falling when standing up quickly, muscle pain, weakness, twitches, dizziness, and anxiety.[6][7] Extrapyramidal symptoms are also common and include tremor, dystonia (sustained or repetitive muscle contractions), akathisia (the feeling of a need to be in motion), parkinsonism, and muscle rigidity; in a 2013 meta-analysis of 15 antipsychotic drugs, ziprasidone ranked 8th for such side effects.[14]

Ziprasidone is known to trigger mania in some bipolar patients.[15][16][17]

This medication can cause birth defects, according to animal studies, although this side effect has not been confirmed in humans.[2]

Recently, the FDA required the manufacturers of some atypical antipsychotics to include a warning about the risk of hyperglycemia and Type II diabetes with atypical antipsychotics. Some evidence suggests that ziprasidone does not cause insulin resistance to the degree of other atypical antipsychotics, such as olanzapine. Weight gain is also less of a concern with ziprasidone compared to other atypical antipsychotics.[18][19][20][21] In fact, in a trial of long term therapy with ziprasidone, overweight patients (BMI > 27) actually had a mean weight loss overall.[2] According to the manufacturer insert, ziprasidone caused an average weight gain of 2.2 kg (4.8 lbs), which is significantly lower than other atypical antipsychotics, making this medication better for patients that are concerned about their weight. In December 2014, the FDA warned that ziprasidone could cause a potentially fatal skin reaction, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), although this was believed to occur only rarely.[22]

Discontinuation

[edit]

The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse.[23] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.[24] Other symptoms may include restlessness, increased sweating, and trouble sleeping.[24] Less commonly there may be a feeling of the world spinning, numbness, or muscle pains.[24] Symptoms generally resolve after a short period of time.[24]

There is tentative evidence that discontinuation of antipsychotics can result in psychosis.[25] It may also result in reoccurrence of the condition that is being treated.[26] Rarely tardive dyskinesia can occur when the medication is stopped.[24]

Pharmacology

[edit]

Pharmacodynamics

[edit]
See also: Atypical antipsychotic § Pharmacodynamics, and Antipsychotic § Comparison of medications
Ziprasidone[27]
Site Ki (nM) Action Ref
SERTTooltip Serotonin transporter 112 Blocker [27]
NETTooltip Norepinephrine transporter 44 Blocker [27]
DATTooltip Dopamine transporter 10000+ ND [27]
5-HT1A 2.5–76 Partial agonist [28][29][30]
5-HT1B 0.99–4.0 Partial agonist [29][27]
5-HT1D 5.1–9.0 Partial agonist [29][27]
5-HT1E 360–1279 ND [29][27]
5-HT2A 0.08–1.4 Antagonist [31][28][29]
5-HT2B 27.2 Antagonist [27]
5-HT2C 0.72–13 Antagonist [28]
5-HT3 10000+ ND [27]
5-HT5A 291 ND [27]
5-HT6 61–76 Antagonist [30][28]
5-HT7 6.0–9.3 Antagonist [27][30][28]
α1A 18 Antagonist [27][30]
α1B 9.0 Antagonist [27]
α2A 160 Antagonist [27][29][30]
α2B 48 Antagonist [27][29][30]
α2C 59–77 Antagonist [27][29][30]
β1 2570+ ND [29][27]
β2 10000+ ND [29][27]
D1 30–130 ND [27][28]
D2 4.8 Antagonist [32][28][30]
D2L 4.6 Antagonist [29][33]
D2S 4.2 Antagonist [29]
D3 7.2 Antagonist [32][28][29]
D4 0.8–105 Antagonist [32][28][27]
D4.2 28–39 Antagonist [33]
D4.4 14.9 Antagonist [34]
D5 152 ND [27]
H1 15–130 Antagonist [29][28][27]
H2 3500+ ND [27]
H3 10000+ ND [27]
H4 10000+ ND [27]
M1 300+ ND [35][27][28]
M2 3000+ ND [35][27]
M3 1300+ ND [35][30][27]
M4 1600+ ND [35][27]
M5 1600+ ND [35][27]
σ1 110 ND [29]
σ2 ND ND ND
Opioid 1000+ ND [29]
nAChTooltip Nicotinic acetylcholine receptor 10000+ ND [27]
NMDA
(PCP)		 10000+ ND [27]
VDCCTooltip Voltage-dependent calcium channel 10000+ ND [27][29]
VGSCTooltip Voltage-gated sodium channel 2620 ND [29]
hERGTooltip Human Ether-à-go-go-Related Gene 169 Blocker [36]
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. All data are for human cloned proteins, except H3 (guinea pig), σ1 (guinea pig), opioid (rodent), NMDA/PCP (rat), VDCC, and VGSC.[27]

Correspondence to clinical effects

[edit]

Ziprasidone mostly affects the receptors of dopamine (D2), serotonin (5-HT2A, partially 5-HT1A, 5-HT2C, and 5-HT1D)[3][37][38] and epinephrine/norepinephrine (α1) to a high degree, while of histamine (H1) - moderately.[39][40] It also somewhat inhibits reuptake of serotonin and norepinephrine, though not dopamine.[39][41]

Ziprasidone's efficacy in treating the positive symptoms of schizophrenia is believed to be mediated primarily via antagonism of the dopamine receptors, specifically D2. Blockade of the 5-HT2A receptor may also play a role in its effectiveness against positive symptoms, though the significance of this property in antipsychotic drugs is still debated among researchers.[42] Blockade of 5-HT2A and 5-HT2C and activation of 5-HT1A as well as inhibition of the reuptake of serotonin and norepinephrine may all contribute to its ability to alleviate negative symptoms.;[43] however, its effects on the 5-HT1A receptor may be limited as a study[44] found ziprasidone would likely "produce detectable occupancy [of 5-HT1A receptors] only at higher doses that would produce unacceptable levels of side effects in man, although lower doses are sufficient to produce pharmacological effects." The relatively weak antagonistic actions of ziprasidone on the α1-adrenergic receptor likely in part explains some of its side effects, such as orthostatic hypotension. Unlike many other antipsychotics, ziprasidone has no significant affinity for the mACh receptors, and as such lacks any anticholinergic side effects. Like most other antipsychotics, ziprasidone is sedating due primarily to serotonin and dopamine blockade.[45][46]

Pharmacokinetics

[edit]

The systemic bioavailability of ziprasidone is 100% when administered intramuscularly and 60% when administered orally without food.[3]

After a single dose intramuscular administration, the peak serum concentration typically occurs at about 60 minutes after the dose is administered, or earlier.[47] Steady state plasma concentrations are achieved within one to three days. Exposure increases in a dose-related manner and following three days of intramuscular dosing, little accumulation is observed.

The bioavailability of the drug is reduced by approximately 50% if a meal is not eaten before Ziprasidone ingestion.[2][48]

Ziprasidone is hepatically metabolized by aldehyde oxidase; minor metabolism occurs via cytochrome P450 3A4 (CYP3A4).[49] Medications that induce (e.g. carbamazepine) or inhibit (e.g. ketoconazole) CYP3A4 have been shown to decrease and increase, respectively, blood levels of ziprasidone.[50][51]

Its biological half-life time is 10 hours at doses of 80–120 milligrams.[4]

History

[edit]

Ziprasidone is chemically similar to risperidone,[52] of which it is a structural analogue.[53] It was first synthesized in 1987 at the Pfizer central research campus in Groton, Connecticut.[54]

Phase I trials started in 1995.[55] In 1998 ziprasidone was approved in Sweden.[56][57] After the FDA raised concerns about long QT syndrome, more clinical trials were conducted and submitted to the FDA, which approved the drug on February 5, 2001.[55][58][59]

Society and culture

[edit]

Lawsuit

[edit]

In September 2009, the U.S. Justice Department announced that Pfizer had been ordered to pay a historic fine of $2.3 billion as a penalty for fraudulent marketing of several drugs, including Geodon.[60]

Brand names

[edit]

In the US, Geodon is marketed by Viatris after Upjohn was spun off from Pfizer.[61][62][63]

Research

[edit]

Ziprasidone has been studied in and reported to be effective in the treatment of borderline personality disorder, but findings are mixed.[64][65][66][67]

References

[edit]

Further reading

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Ziprasidone

View on Grokipedia
from Grokipedia
Ziprasidone is an medication primarily used to treat and in adults. Marketed under the brand name Geodon by , it is available in oral capsule form (20 mg, 40 mg, 60 mg, 80 mg) and as an (20 mg/mL) for acute use. Approved by the U.S. (FDA) in 2001, ziprasidone is indicated for the treatment of , where it has demonstrated efficacy in reducing symptoms over 4- to 6-week clinical trials using scales such as the Brief Psychiatric Rating Scale (BPRS) and (PANSS). It is also approved for the acute treatment of manic or mixed episodes associated with , with evidence from two 3-week trials showing improvements in Young Mania Rating Scale (YMRS) scores at doses of 40-80 mg twice daily, and for maintenance treatment as an adjunct to or to delay relapse. The intramuscular formulation is specifically indicated for the short-term management of acute agitation in patients with , supported by two placebo-controlled trials. However, ziprasidone is not approved for use in patients with dementia-related due to increased mortality risk in elderly populations. The of ziprasidone remains unknown, but it is believed to involve antagonism at D2 and serotonin 5-HT2A receptors, similar to other atypical antipsychotics effective in and . It exhibits high binding affinity for multiple receptors, including antagonism at D2, D3, 5-HT2A, 5-HT2C, 5-HT1D, α1-adrenergic, and H1-histaminergic sites, as well as partial at 5-HT1A receptors and inhibition of serotonin and norepinephrine . Pharmacokinetically, ziprasidone has a of approximately 7 hours, with that doubles when taken with food, and it is primarily metabolized in the liver via aldehyde oxidase and enzymes (). Common side effects include , , and , with a notable risk of prolongation that requires monitoring.

Medical Uses

Indications

Ziprasidone is approved by the (FDA) for the treatment of in adults, encompassing both acute exacerbations and maintenance therapy to prevent relapse. It is also indicated for the acute treatment of manic or mixed episodes associated with , with or without psychotic features, as monotherapy in adults. Additionally, the oral formulation supports maintenance treatment of as an adjunct to or in adults, reducing the risk of mood episode recurrence. The intramuscular formulation is specifically approved for the acute treatment of agitation in adult patients with who require short-term management with an injectable . Clinical trials have demonstrated ziprasidone's efficacy in , with pivotal placebo-controlled studies showing significant reductions in both positive and negative symptoms. In short-term trials, ziprasidone at doses of 80 mg/day and 160 mg/day produced greater improvements in (PANSS) total scores compared to , with mean reductions of approximately 20-25 points versus 10-15 points for , corresponding to response rates of 30-40% versus 15-20%. For negative symptoms, ziprasidone showed superior PANSS negative subscale improvements over (p < 0.05) in a 1-year double-blind trial. In bipolar mania, three-week placebo-controlled trials reported significant mood stabilization, with ziprasidone reducing Young Mania Rating Scale (YMRS) total scores by a least squares mean of -17.0 points compared to -9.5 points for (p < 0.001), alongside improvements in positive psychotic symptoms on the PANSS. Off-label uses of ziprasidone include adjunctive therapy for major depressive disorder (MDD), particularly in cases with partial response to antidepressants, though evidence is mixed and primarily from small randomized trials. In an 8-week double-blind study, adjunctive ziprasidone (40-160 mg/day) added to escitalopram significantly improved Montgomery-Åsberg Depression Rating Scale (MADRS) scores versus placebo in adults with MDD (p = 0.015), but benefits were not consistent for cognitive symptoms. For treatment-resistant depression, augmentation with ziprasidone has shown increased response rates (number needed to treat = 7) in meta-analyses of trials, yet with limitations including higher risks of adverse events like akathisia. In autism spectrum disorder, ziprasidone is used off-label for irritability, with naturalistic studies in youth reporting reductions in aberrant behavior checklist-irritability subscale scores (mean decrease of 50-60%) at doses of 20-80 mg/day, but evidence is limited to open-label and retrospective designs without robust placebo controls, and long-term safety data are sparse.

Dosage and Administration

Ziprasidone is available in oral capsule formulations of 20 mg, 40 mg, 60 mg, and 80 mg strengths, as well as an intramuscular (IM) injection in 20 mg/mL single-dose vials. For schizophrenia, the recommended initial oral dose is 20 mg twice daily with food, with titration in increments of no more than 20 mg per day to a target range of 40 mg to 80 mg twice daily (80-160 mg/day total), based on clinical response and tolerability; the maximum recommended dose is 80 mg twice daily. For acute agitation associated with schizophrenia, the IM dose is 10 mg injected every 2 hours or 20 mg every 4 hours as needed, not to exceed 40 mg per day, with IM use limited to no more than 3 consecutive days before transitioning to oral therapy. In bipolar I disorder with acute manic or mixed episodes, oral dosing begins at 40 mg twice daily on day 1, increasing to 60 mg to 80 mg twice daily on day 2 if tolerated, with a maintenance range of 40-80 mg twice daily. Oral capsules must be taken with food (approximately 500 calories), as this increases bioavailability by up to twofold compared to the fasting state, which is essential for achieving therapeutic plasma levels. Capsules should be swallowed whole without splitting, chewing, or crushing. For IM administration, the vial must be reconstituted with 1.2 mL of sterile water for injection to yield 20 mg/mL, intended solely for intramuscular use and not for intravenous administration; any unused portion after reconstitution should be discarded. Monitoring includes a baseline electrocardiogram (ECG) to assess QT interval prolongation risk, with periodic ECGs recommended thereafter, particularly in patients with cardiac risk factors; serum potassium and magnesium levels should also be checked in at-risk individuals. Additionally, baseline and follow-up assessments of weight, fasting lipid profile, and fasting blood glucose are advised at 3 months and annually, in line with guidelines for atypical antipsychotics. Dose adjustments are recommended for elderly patients, starting at the lower end of the dosing range (e.g., 20 mg daily or less) with slower titration and closer monitoring due to increased sensitivity. No oral dose adjustment is needed for mild to moderate hepatic or renal impairment, though caution is advised for IM use in severe renal impairment due to the sulfobutyl ether beta-cyclodextrin excipient; in hepatic cirrhosis, exposure may increase, warranting careful titration. Concomitant use of strong inhibitors (e.g., ketoconazole 400 mg/day) increases ziprasidone AUC and Cmax by approximately 35-40%; no dose adjustment is recommended, but monitor closely for adverse effects.

Contraindications and Precautions

Contraindications

Ziprasidone is contraindicated in patients with a known hypersensitivity to the drug or any of its components, as severe allergic reactions may occur upon exposure. Due to its dose-dependent prolongation of the QT interval, which increases the risk of serious ventricular arrhythmias such as , ziprasidone must not be administered to individuals with a known history of QT prolongation (including congenital long QT syndrome), recent acute myocardial infarction, or uncompensated heart failure. Concurrent use with other medications that prolong the QT interval is also absolutely contraindicated to prevent additive effects; examples include antiarrhythmics like and , antipsychotics such as and , and antibiotics including and sparfloxacin. Ziprasidone is contraindicated in patients who are taking monoamine oxidase inhibitors (MAOIs), including and intravenous methylene blue, or who have taken MAOIs within 14 days, because of the risk of . The U.S. Food and Drug Administration (FDA) prescribing information for ziprasidone includes a black box warning highlighting the increased risk of death in elderly patients with dementia-related psychosis treated with antipsychotic medications, emphasizing the need to avoid use in this population due to heightened cardiac and other vulnerabilities. To mitigate these risks, patient screening prior to initiation should include a detailed allergy history to rule out hypersensitivity and a baseline electrocardiogram (ECG) to evaluate QT interval and identify underlying cardiac conditions.

Warnings and Special Populations

Ziprasidone carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis, with analyses of placebo-controlled trials showing a 1.6-1.7 times higher risk of death compared to placebo, primarily due to cardiovascular or infectious causes; it is not approved for this indication. In geriatric patients without dementia, no overall differences in safety were observed, but greater sensitivity may necessitate a lower starting dose and slower titration. For hepatic impairment, exposure increases modestly (AUC by 13% in Child-Pugh A and 34% in Child-Pugh B), but no specific dose adjustment is recommended; caution is advised in severe cases (Child-Pugh C) due to limited data. In renal impairment, pharmacokinetics are minimally affected for oral formulations since less than 1% is excreted unchanged in urine, though the intramuscular form requires caution due to the sulfobutyl ether beta-cyclodextrin excipient, which may accumulate in patients with creatinine clearance below 50 mL/min. Dose reductions may be considered in these populations based on tolerability. Animal reproduction studies have shown that ziprasidone may cause developmental toxicity, including possible teratogenic effects; there are no adequate and well-controlled studies in humans. Limited data from pregnancy exposure registries involving over 1800 cases suggest no increased risk of major birth defects. Third-trimester exposure may cause neonatal extrapyramidal symptoms or withdrawal. Pregnant patients should be advised of potential risks, use effective contraception if appropriate, monitor neonates closely, and enroll in the National Pregnancy Registry for Atypical Antipsychotics. During lactation, ziprasidone is present in breast milk in low amounts; breastfeeding is not recommended, or infants should be monitored for sedation, irritability, poor feeding, or extrapyramidal symptoms if continued. Pediatric use of ziprasidone is not approved by the FDA for patients under 18 years, as safety and efficacy have not been established; off-label use in adolescents requires careful risk-benefit assessment due to potential for metabolic and neurological effects. Additional warnings include risks of and new-onset diabetes, particularly in patients with predisposing factors, as well as dyslipidemia and weight gain, which may contribute to ; , a potentially fatal reaction involving hyperthermia and rigidity; , with higher risk from prolonged use; and increased suicidality in young adults aged 18-24 during initial treatment. Patients at elevated suicide risk should receive close supervision and the smallest effective prescription quantity. Monitoring protocols for special populations emphasize baseline and periodic assessments: metabolic screening including fasting glucose, lipids, and weight at baseline, 3 months, and annually thereafter (or every 3-6 months initially if high-risk); electrolytes in those with predisposing factors; and close observation for NMS or tardive dyskinesia signs.

Adverse Effects and Safety

Common Adverse Effects

Common adverse effects of ziprasidone, observed in placebo-controlled clinical trials, primarily include somnolence, dizziness, and nausea, which occur at rates exceeding 10% in patients with or bipolar mania. In short-term trials for , somnolence affected 14% of ziprasidone-treated patients compared to 7% on placebo, dizziness occurred in 8% versus 6%, and nausea in 10% versus 7%. For bipolar mania, these rates were higher for somnolence (31% versus 12%) and dizziness (16% versus 7%), with nausea remaining at 10% versus 7%. These effects are generally mild and manageable, often leading to discontinuation in fewer than 5% of cases. Gastrointestinal disturbances are also frequent, with dyspepsia reported in 8% of schizophrenia patients (versus 7% placebo) and constipation in 9% (versus 8%). These symptoms, along with nausea, may relate briefly to ziprasidone's serotonin receptor antagonism. Neurological effects include extrapyramidal symptoms (EPS), such as akathisia, at lower rates than typical antipsychotics; akathisia incidence was 8% in schizophrenia trials (versus 7% placebo) and 10% in bipolar trials (versus 5%). Orthostatic hypotension, manifesting as lightheadedness, occurred in about 5% of intramuscular administration cases. Other common effects include rhinitis (4%) and headache (>10%). Ziprasidone is associated with minimal compared to other antipsychotics, with a median increase of 0.5 kg in short-term trials and only 10% of patients experiencing a ≥7% body increase (versus 4% ). In the CATIE study of chronic , ziprasidone was weight-neutral and showed favorable metabolic effects, with no significant increases in or . Most adverse effects peak within the first few weeks of treatment and often resolve with continued use, dose adjustment, or supportive measures; incidence data derive from placebo-controlled trials involving thousands of patients across and bipolar populations.
Adverse EffectIncidence in Schizophrenia Trials (Ziprasidone vs. Placebo)Incidence in Bipolar Mania Trials (Ziprasidone vs. Placebo)
14% vs. 7%31% vs. 12%
8% vs. 6%16% vs. 7%
10% vs. 7%10% vs. 7%
Dyspepsia8% vs. 7%Not ≥2% difference
9% vs. 8%Not ≥2% difference
8% vs. 7%10% vs. 5%
Weight Gain (≥7%)10% vs. 4%2.4–4.4% vs. 1.8%

Serious Adverse Effects

Ziprasidone, an , is associated with several serious adverse effects that require careful monitoring, particularly in vulnerable patients. These include potentially life-threatening cardiovascular, metabolic, neurological, hematologic, and other events, with incidences generally low but significant enough to warrant precautions. , including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Stevens-Johnson syndrome, have been reported; immediate discontinuation is recommended if suspected. Cardiovascular risks are prominent, primarily involving QTc interval prolongation due to blockade of the hERG potassium channel, which can lead to and sudden cardiac death in predisposed individuals. Clinical trials showed an average QTc increase of about 10 ms at doses up to 160 mg/day, with 0.06% of patients experiencing QTc exceeding 500 ms; the risk of remains below 1%. Post-marketing reports have documented rare cases of ventricular arrhythmias and sudden death, particularly in patients with risk factors such as , hypokalemia, hypomagnesemia, congenital , recent , uncompensated , or concurrent use of QT-prolonging drugs. sex further elevates this risk. Baseline ECG and periodic monitoring of QTc, serum electrolytes, and avoidance of contraindicated agents are recommended. Metabolic disturbances include new-onset mellitus and , which can contribute to long-term morbidity. leading to or hyperosmolar coma has been reported, with approximately 1-2% incidence of new-onset in treated populations, higher in those with or family history. manifests as elevated triglycerides (e.g., ≥50 mg/dL increase in about 34% of patients in trials) and changes. Monitoring of fasting glucose and lipid profiles at baseline and periodically, especially in at-risk patients, is advised to detect these effects early. Neurological serious effects encompass (NMS) and seizures. NMS, a rare but potentially fatal reaction occurring in less than 0.1% of cases, presents with hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability; immediate discontinuation and supportive care are essential. Seizures have been observed in 0.1-0.4% of patients, necessitating caution in those with a history of or conditions lowering the . Hematologic adverse effects such as and are rare but serious, potentially leading to severe infections. These require frequent monitoring, particularly in the first few months or in patients with pre-existing low counts or prior drug-induced ; discontinuation is indicated if falls below 1000/mm³ without other etiology. Other notable risks include , particularly in younger patients with psychotic or bipolar disorders, and , a rare urologic emergency reported in isolated cases. Close supervision of high-risk individuals for worsening depression or suicidality, along with the smallest effective prescription quantity, is crucial. The FDA has issued a warning highlighting a 1.6-1.7-fold increased mortality risk (primarily from cardiovascular or infectious causes) in elderly patients with dementia-related treated with ziprasidone, and it is not approved for this indication.

Discontinuation Effects

Discontinuation of ziprasidone, an , can lead to withdrawal symptoms due to dopaminergic supersensitivity and rapid offset of its effects, given its relatively short of approximately 7 hours. Common withdrawal phenomena include rebound , , , and anxiety, which may emerge as a result of abrupt cessation rather than of the underlying condition. In specific cases, such as dose reductions or sudden stops, patients have experienced characterized by intense motor restlessness and an urge to move. These symptoms typically onset within 1-4 days after discontinuation and last 1-2 weeks, though motor effects like can resolve faster with . To minimize risks, tapering ziprasidone is recommended over 1-4 weeks for short-term use, with slower reductions (e.g., over several months) for patients on long-term therapy exceeding 6 months, allowing time for receptor adaptations to normalize. This approach involves gradual dose decreases, such as 20-25% every few days initially, monitored closely for emerging symptoms, as no standardized protocol exists specifically for ziprasidone but general guidelines emphasize individualized hyperbolic tapering to maintain low D2 receptor occupancy. Risk factors for significant discontinuation effects include abrupt cessation, high doses (e.g., >80 mg/day), and prolonged therapy, which heighten the likelihood of supersensitivity psychosis or movement disorders. Observational studies on atypical antipsychotics indicate that 20-30% of patients experience mild withdrawal symptoms like anxiety or insomnia with abrupt stops, compared to under 5% with proper tapering, though data specific to ziprasidone are limited to case reports. For instance, a case report documented rapid-onset psychosis in an adolescent female after abrupt ziprasidone termination, resolving upon reinitiation, highlighting vulnerability in younger patients. If or severe withdrawal occurs, reinitiation of ziprasidone at a low dose with rapid is advised, often leading to symptom resolution within days, as seen in reported cases of and . Close clinical monitoring is essential during this process to differentiate withdrawal from disease recurrence.

Overdose

Symptoms and Signs

Ziprasidone overdose typically presents with central nervous system depression, manifesting as or drowsiness, which is the most commonly reported acute symptom. Other early signs include slurred speech, , anxiety, and such as uncontrollable shaking or sudden involuntary movements. The clinical presentation is often dose-dependent, with mild overdoses (approximately 100-500 mg) primarily causing and mild gastrointestinal upset like or . In severe cases exceeding 1000 mg, more serious effects emerge, including , , QTc interval prolongation (often >500 ms), seizures, and progression to . Vital sign abnormalities in overdose frequently involve cardiovascular instability, such as (heart rate >100 bpm), alongside that may require intervention. Prolonged QTc intervals represent a critical risk, potentially leading to , though this is uncommon in isolated ziprasidone ingestions. Neurologically, patients may exhibit agitation, exacerbation of (e.g., or ), and in severe overdoses, respiratory depression or fluctuating mental status progressing to unresponsiveness. is also observed, likely due to antagonism. Fatalities from ziprasidone overdose are rare and typically occur in the context of , such as concurrent use of alcohol, opioids, benzodiazepines, or other sedatives, which exacerbate respiratory depression and hemodynamic instability; isolated ingestions seldom result in death. For instance, case reports describe survival after ingestions up to 4480 mg when co-ingestants were present but managed promptly, underscoring the role of multiple agents in adverse outcomes.

Management and Treatment

Management of ziprasidone overdose primarily involves supportive care, with no specific antidote available. Initial assessment should prioritize the ABCs—airway, breathing, and circulation—to stabilize the patient, including establishing intravenous access and ensuring adequate ventilation, with intubation considered if respiratory compromise occurs. Gastrointestinal decontamination with activated charcoal is recommended if ingestion occurred within 1 to 2 hours and the patient is alert or intubated, though gastric lavage is rarely performed and reserved for cases with large recent ingestions in unprotected airways. Cardiac monitoring is essential due to the risk of prolongation and ; continuous electrocardiogram (ECG) surveillance should be instituted upon presentation, with serial ECGs to assess for . If QT prolongation is detected, intravenous (typically 1 to 2 g diluted and infused over 5 to 60 minutes, repeatable if necessary) is administered to mitigate risk, while avoiding concomitant use of other QT-prolonging agents such as certain anti or antibiotics. Symptomatic treatments address specific manifestations, including benzodiazepines (e.g., or ) for agitation or seizures, and intravenous fluids or vasopressors for unresponsive to initial . Enhanced elimination techniques like are ineffective owing to ziprasidone's high protein binding (>99%), which limits dialyzability, as influenced by its pharmacokinetic profile of extensive hepatic metabolism and low renal excretion. For disposition, patients with severe features such as arrhythmias, , or hemodynamic instability require admission for close monitoring, while those with mild symptoms may be observed for 24 to 48 hours in a general ward, as delayed effects are uncommon beyond 6 to 12 hours post-ingestion. Data from U.S. Poison Control Centers (2000–2014) indicate favorable outcomes with these supportive measures, reporting 12,587 single-substance ziprasidone exposures with only 9 deaths, yielding a of less than 0.1%.

Pharmacology

Pharmacodynamics

Ziprasidone is an that exerts its effects primarily through antagonism at D₂ and serotonin 5-HT₂A receptors, with additional activity at other receptors. It demonstrates high binding affinity for the D₂ receptor (Kᵢ = 4.8 nM, ), D₃ receptor (Kᵢ = 7.2 nM, ), serotonin 5-HT₂A receptor (Kᵢ = 0.4 nM, ), 5-HT₁D receptor (Kᵢ = 2 nM, ), and serotonin 5-HT₂C receptor (Kᵢ = 1.3 nM, ), as well as the serotonin 5-HT₁A receptor (Kᵢ = 3.4 nM, ), along with moderate affinity for the α₁-adrenergic receptor (Kᵢ = 10 nM, ) and H₁ receptor (Kᵢ = 47 nM, ). Ziprasidone also inhibits at serotonin (IC₅₀ ≈ 29 nM) and norepinephrine (IC₅₀ ≈ 160 nM) transporters, contributing to potential and effects, with no significant affinity for the (IC₅₀ >10,000 nM). In the treatment of , ziprasidone's antagonism of D₂ receptors in the reduces positive symptoms such as hallucinations and delusions by modulating excessive activity. Concurrent antagonism at 5-HT₂A receptors enhances and serotonergic transmission in the , contributing to improvements in negative symptoms like social withdrawal and cognitive deficits. The partial agonism at 5-HT₁A receptors may further support efficacy by promoting serotonin release and reducing anxiety-related symptoms. For bipolar disorder, ziprasidone's modulation of serotonin receptors, particularly through 5-HT₂A antagonism and 5-HT₁A partial agonism, is thought to stabilize mood during manic episodes by balancing serotonergic tone and indirectly influencing . This receptor profile underpins its antimanic effects, though the exact mechanisms remain partially understood beyond established clinical efficacy. Adverse effects of ziprasidone are linked to its broader receptor interactions; H₁ receptor antagonism contributes to and , while α₁-adrenergic can cause . The drug's relatively low risk of (EPS) is attributed to modest D₂ receptor occupancy of approximately 50-70% at therapeutic doses (e.g., 80-160 mg/day), which avoids excessive striatal compared to typical antipsychotics. Additionally, despite 5-HT₂C antagonism—which is associated with in some antipsychotics—ziprasidone exhibits minimal metabolic impact, possibly due to its balanced serotonin-dopamine profile and reuptake inhibition properties.
ReceptorAffinity (Kᵢ, nM)ActivityLinked Clinical Outcome
D₂4.8Reduces positive symptoms in ; modest occupancy (50-70%) limits EPS risk
D₃7.2May contribute to efficacy against negative symptoms and cognitive deficits
5-HT₂A0.4Improves negative and cognitive symptoms; contributes to mood stabilization in
5-HT₁A3.4Enhances antipsychotic and antimanic effects via serotonin modulation
5-HT₂C1.3Associated with low liability despite antagonism
5-HT₁D2Potential role in modulating serotonergic tone
α₁10
H₁47 and

Pharmacokinetics

Ziprasidone exhibits variable absorption depending on the and the presence of . Following , the absolute is approximately 60% when taken with , compared to about 30% in the fasting state, with peak plasma concentrations (T_max) achieved in 6 to 8 hours. The absorption is increased up to twofold when administered with a containing at least 500 calories, regardless of fat content, leading to a corresponding increase in area under the curve (AUC). Intramuscular () administration provides nearly complete of 100%, with rapid within 15 to 30 minutes and peak concentrations typically occurring around post-dose. The drug is widely distributed throughout the body, with a mean apparent (V_d) of 1.5 L/kg. Ziprasidone is highly bound to plasma proteins, exceeding 99%, primarily to and α1-acid . Ziprasidone undergoes extensive hepatic metabolism, with approximately one-third of clearance mediated by oxidation (primarily ) and two-thirds via reductive pathways involving aldehyde oxidase and S-transferase. Major metabolites include benzisothiazole , benzisothiazole , ziprasidone , and S-methyldihydroziprasidone, the latter being an . Elimination occurs primarily through (about 66%) and (about 20%), with less than 1% and 4% of the dose excreted unchanged in and , respectively. The mean terminal is approximately 7 hours for and 2 to 5 hours for IM, with steady-state concentrations reached within 1 to 3 days of multiple dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Steady-state plasma concentrations (C_ss) can be estimated using the formula: Css=F⋅Dose/τCLC_{ss} = \frac{F \cdot Dose / \tau}{CL} where FF is (e.g., 0.6 with ), Dose is the administered dose, τ\tau is the dosing interval, and CLCL is clearance. Pharmacokinetic parameters show no clinically significant differences based on or age, including in elderly patients over 65 years, though caution is advised in hepatic or renal impairment due to potential alterations in clearance. The effect on AUC underscores the recommendation to administer oral ziprasidone with meals to optimize .

Drug Interactions

Pharmacokinetic Interactions

Ziprasidone undergoes oxidative metabolism primarily via the enzyme, accounting for less than one-third of its total metabolism, which makes it susceptible to pharmacokinetic interactions with modulators. Potent inhibitors, such as , have been shown to modestly increase ziprasidone exposure; in a placebo-controlled crossover study, co-administration of 400 mg once daily for 5 days increased the area under the curve (AUC) and maximum concentration (Cmax) of ziprasidone by approximately 33% and 34%, respectively. Similar effects are anticipated with other strong inhibitors like or , though no specific dose reductions are routinely recommended due to the modest magnitude of the change; clinical monitoring for efficacy and adverse effects is advised instead. In contrast, inducers significantly reduce ziprasidone plasma levels, potentially necessitating dose increases to maintain therapeutic efficacy. , a strong inducer, decreased ziprasidone AUC by about 35% when co-administered at 200 mg twice daily for 21 days, with greater reductions possible at higher doses. Comparable decreases in exposure are expected with other potent inducers such as rifampin and , based on their shared mechanism of induction, though dedicated interaction studies for these agents are limited. Food substantially enhances ziprasidone's , with absorption increasing up to twofold when administered with meals, particularly those high in and calories (at least 500 calories); the absolute bioavailability of a 20 mg dose reaches approximately 60% under fed conditions compared to lower values in the fasting state. Therefore, ziprasidone capsules should always be taken with food to optimize . Ziprasidone is not a significant substrate for (P-gp), minimizing interactions with P-gp modulators, and it exhibits no major pharmacokinetic interactions via renal pathways, as less than 5% is excreted unchanged in . In patients receiving involving modulators, monitoring of clinical response or plasma concentrations may be warranted to guide dose adjustments.

Pharmacodynamic Interactions

Ziprasidone's pharmacodynamic interactions stem from its multifaceted receptor profile, including antagonism at D2, serotonin 5-HT2A, and other receptors, which can lead to additive or antagonistic physiological effects when combined with other medications. These interactions occur at the functional level without necessarily altering drug concentrations, potentially amplifying adverse effects such as cardiac, neurological, or autonomic disturbances. A primary concern is prolongation, as ziprasidone dose-dependently extends the QTc interval by approximately 10-20 msec, increasing the risk of (TdP). This effect is additive with other QT-prolonging agents, including Class Ia and III antiarrhythmics (e.g., , quinidine, , ), other antipsychotics (e.g., , ), and antidepressants (TCAs) like amitriptyline. The FDA contraindicates ziprasidone use with such drugs, particularly in patients with cardiac risk factors, and CredibleMeds categorizes ziprasidone as having a known risk of TdP, recommending ECG monitoring and risk stratification tools like the Tisdale score for scenarios. Case reports have documented severe arrhythmias in these combinations, underscoring the need for alternative therapies when possible. Central nervous system (CNS) depression is another key interaction, where ziprasidone's sedative properties enhance the effects of benzodiazepines, opioids, and alcohol, leading to profound , respiratory depression, or impaired psychomotor function. Guidelines advise caution or dose adjustments with these CNS depressants to mitigate risks, supported by clinical observations of increased adverse events in co-administration. Similarly, ziprasidone's alpha-1 adrenergic antagonism can synergize with antihypertensives or alpha-blockers, potentiating and , particularly during initial dosing. Although ziprasidone exhibits minimal intrinsic activity, its combination with other antipsychotics or antihistamines possessing anticholinergic effects may result in additive symptoms such as dry mouth, , or . For (EPS), ziprasidone's D2 receptor blockade can antagonize the therapeutic effects of levodopa in and exacerbate EPS when paired with dopamine-depleting agents like metoclopramide, as evidenced by case reports and pharmacological principles. These interactions are highlighted in prescribing guidelines to guide safer concurrent use.

Chemistry

Chemical Structure and Properties

Ziprasidone, with the systematic IUPAC name 5-[2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, has the molecular formula \ceC21H21ClN4OS\ce{C21H21ClN4OS} and a molecular weight of 412.94 g/mol. The molecule consists of a ring that connects a 1,2-benzisothiazol-3-yl moiety to an ethyl linker attached at the 5-position of a 6-chloro-substituted 1,3-dihydro-2H-indol-2-one core. The chloro group at the 6-position of the indole ring represents a critical structural element influencing its chemical behavior. As a solid, ziprasidone appears as a to slightly and exhibits poor , with a solubility of approximately 0.3–0.5 μg/mL (0.0003–0.0005 g/L) at neutral pH for the . It possesses moderate , characterized by a logP value of 3.8, and a pKa of approximately 6.9 associated with its nitrogen, reflecting its weakly basic nature. Ziprasidone demonstrates sensitivity to and elevated temperatures, with degradation observed under photolytic conditions and . It is stable when stored at controlled (15–30°C) in a tightly closed , protected from and .

Formulation and Stability

Ziprasidone is formulated primarily as oral hard capsules containing ziprasidone hydrochloride monohydrate as the active ingredient, along with such as monohydrate, pregelatinized , and to aid in compression and flow during . The capsule shells consist of , , and sodium lauryl sulfate, with FD&C Blue No. 1 added to the 20 mg and 80 mg variants for color differentiation. For acute agitation, an intramuscular () suspension is available as ziprasidone trihydrate in lyophilized form, reconstituted with sterile to yield a 20 mg/mL solution; this formulation incorporates sulfobutylether beta-cyclodextrin sodium as a solubilizing to enhance the drug's poor aqueous . These address ziprasidone's classification as a () Class II drug, characterized by low (approximately 0.3–0.5 μg/mL in for the ) and high permeability, through strategies like salt formation and particle to improve dissolution rates. Generic versions of ziprasidone must demonstrate to the branded Geodon () product, including comparable dissolution profiles across strengths (20 mg, 40 mg, 60 mg, and 80 mg for capsules), as outlined in FDA bioequivalence guidance. This ensures that generics match the reference product's pharmacokinetic performance, particularly under fed conditions where is enhanced due to formulation-specific improvements. The expiration of key U.S. patents, such as those covering the salt and injection (e.g., U.S. No. 5,312,925), between 2012 and 2014 facilitated the market entry of multiple generics, broadening access without altering core formulation requirements. Ziprasidone formulations exhibit a of approximately 2 years when stored under controlled conditions (15–30°C or 59–86°F), with protection from light and moisture recommended to prevent degradation. The drug is susceptible to oxidative and , particularly under alkaline conditions or high humidity, leading to impurities such as hydrolysis products; thermal stress causes mild breakdown, while occurs upon exposure to UV/visible light. For the form, the lyophilized powder remains stable in dry conditions but the reconstituted solution is stable for up to 24 hours at 15–30°C or 7 days at 2–8°C when protected from light; discard any unused solution after these periods. Compounded oral suspensions of ziprasidone maintain chemical and physical stability for up to 2 weeks under at 5°C. No extended-release formulations are commercially available, as the immediate-release designs suffice for twice-daily dosing aligned with the drug's .

History

Development and Discovery

Ziprasidone was developed by Pfizer researchers in the late 1980s as part of efforts to identify novel atypical antipsychotics with improved efficacy and reduced extrapyramidal side effects compared to typical agents. The compound, initially known as CP-88,059, emerged from a medicinal chemistry program targeting serotonin and dopamine receptor modulation, guided by the hypothesis that a high 5-HT2A/D2 affinity ratio would enhance antipsychotic activity while minimizing motor side effects. Key contributors included chemists John A. Lowe III and Arthur A. Nagel, who synthesized early analogs, with the core structure of ziprasidone—a 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2(1H)-indol-2-one—first described in a 1987 patent filing that outlined its preparation via alkylation of a piperazine derivative with an indolinone intermediate. The structural rationale for ziprasidone drew from analogs of , incorporating a heterocyclic scaffold to achieve balanced receptor binding; this design aimed to replicate the serotonin-dopamine antagonism seen in emerging atypicals while optimizing . Preclinical evaluation in the early confirmed its promising profile, demonstrating high affinity for 5-HT2A receptors (Ki = 0.4 nM) relative to D2 (Ki = 4.8 nM), yielding a favorable 5-HT2A/D2 ratio greater than 10, superior to existing s. In animal models, ziprasidone potently inhibited apomorphine-induced climbing and in (ED50 values of 1.8–11 mg/kg) and amphetamine-induced in monkeys at doses producing minimal (ED50 > 50 mg/kg in rats), indicating low liability for . These findings supported advancement to studies, with receptor targets including 5-HT2A and D2 pursued to balance efficacy and tolerability. Phase I and II trials began in the mid-1990s, focusing on safety, tolerability, and in healthy volunteers and patients with . Early data established that ziprasidone's oral approximately doubles when administered with , particularly high-fat meals, due to enhanced absorption, prompting dosing recommendations to mitigate variability. An (IND) application was filed by in 1995 (IND 34,629), marking a key milestone that enabled these initial clinical explorations and paved the way for larger efficacy trials.

Regulatory Approvals and Milestones

Ziprasidone received its initial approval from the U.S. (FDA) on February 5, 2001, for the treatment of in adults. This approval followed extensive clinical trials addressing concerns over potential prolongation, establishing ziprasidone as an option with a focus on in managing positive and negative symptoms of the disorder. In August 2004, the FDA expanded the indication to include the acute treatment of manic or mixed episodes associated with , either as monotherapy or adjunctive therapy to or . In November 2009, the FDA approved ziprasidone for maintenance treatment of as an adjunct to or . The intramuscular formulation was approved on June 21, 2002, specifically for the short-term management of acute agitation in patients with . Internationally, ziprasidone gained approval in in 1998, marking its early entry into the European market under the brand name Zeldox. By 2002, it received broader authorization across member states for , with further expansion in 2005 to include acute manic or mixed episodes in . Today, ziprasidone is available in over 50 countries worldwide, including , , and various nations in and , reflecting its global adoption for treating psychotic disorders. Post-approval, the FDA updated ziprasidone's labeling in 2005 to include a prominent warning regarding the risk of QT prolongation and potential , based on post-marketing surveillance and electrocardiographic data. No major withdrawals or recalls have occurred, though ongoing has led to refinements in risk communication. The labeling includes warnings regarding the risk of metabolic changes, such as , , and , aligning with class-wide concerns for atypical antipsychotics. The U.S. for ziprasidone expired on March 2, 2012, paving the way for generic entry. The first generic versions of ziprasidone hydrochloride capsules were approved and launched in the U.S. market shortly thereafter, with introducing a bioequivalent product on March 3, 2012. As of 2025, ziprasidone is fully available as a generic medication in multiple formulations, with no new indications approved by major regulatory bodies since 2009.

Society and Culture

Brand Names and Availability

Ziprasidone is marketed under the brand name Geodon in the United States by , while in and several other international markets, it is sold as Zeldox. In regions such as , generic formulations are available under names like Zipsydon, produced by Sun Pharmaceutical Industries Ltd. Similarly, in , generic versions are marketed, often under the generic name ziprasidone hydrochloride, following the availability of the branded Zeldox. Ziprasidone is available exclusively by prescription worldwide, classified as a Schedule H drug in and requiring medical authorization in the and due to its use in treating and . In the United States, generic versions became available following the expiration of the primary patent on March 2, 2012, with approvals granted to manufacturers including , Mylan Pharmaceuticals, and . This led to a substantial reduction in costs, from approximately $500 per month for the branded Geodon to around $50 per month for generics, improving accessibility for patients. In the , the relevant expired in 2014, enabling broader generic entry and further cost containment in developed markets. The drug is widely distributed in developed countries through standard pharmaceutical channels, with oral capsules in strengths of 20 mg, 40 mg, 60 mg, and 80 mg, and an injectable form for acute use. However, availability remains limited in low-income countries, primarily due to higher relative costs and challenges in supply chains. Ziprasidone is not classified as a controlled substance under the U.S. Drug Enforcement Administration (DEA) schedules, indicating it has no significant potential for abuse or dependence. It is available worldwide exclusively as a prescription-only medication (Rx-only), requiring a healthcare provider's authorization for dispensing due to its antipsychotic properties and associated risks. In 2009, , the original manufacturer of ziprasidone (marketed as Geodon), settled multiple lawsuits and government investigations related to off-label promotion of the drug, including for unapproved uses in pediatric patients and higher-than-approved dosages. The settlement included a $301 million specifically for off-label marketing of Geodon, as part of a larger $2.3 billion agreement covering several drugs, with additional $33 million paid to 43 states and the District of Columbia for deceptive practices. These cases highlighted concerns over promotion despite known risks, such as prolongation, which can lead to serious cardiac arrhythmias. Early post-approval surveillance raised cardiac safety concerns for ziprasidone, particularly regarding QT prolongation, prompting FDA label updates in 2004 to emphasize monitoring in at-risk patients. A class-wide controversy emerged in 2005 when the FDA issued a warning for all antipsychotics, including ziprasidone, due to a 1.6- to 1.7-fold increased mortality risk in elderly patients with dementia-related , primarily from cardiovascular events or infections. This warning, based on 17 controlled trials, sparked ongoing debates about the appropriateness of use in vulnerable geriatric populations, though ziprasidone's specific risk profile was noted as comparable to other agents in the class. As of 2025, no major ongoing litigation specifically targets ziprasidone, with post-2009 cases largely resolved and focus shifting to other antipsychotics. Ziprasidone is incorporated into clinical registries and programs for antipsychotics, such as the NQF #1879 measure for adherence in treatment, to monitor long-term safety and outcomes.

Research

Clinical Trials and Efficacy Data

Ziprasidone's efficacy in was established through pivotal phase 3 clinical trials conducted in the early , prior to its FDA approval in 2001. Two key placebo-controlled studies—one 4-week (n=139) with doses of 40 and 120 mg/day, and one 6-week (n=419) with doses of 40, 120, and 200 mg/day—involving patients with acute exacerbations of or demonstrated significant symptom reductions on the (PANSS) total scores compared to . The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, a large-scale 2005 trial involving 1,493 patients with chronic , further evaluated ziprasidone's real-world effectiveness. Ziprasidone showed comparable efficacy to in terms of PANSS score improvements over 18 months, though with a higher all-cause discontinuation rate of 79% versus 64% for olanzapine ( 1.28, p=0.02). Notably, ziprasidone was associated with metabolic advantages, including less (mean change -0.04 kg/month) and improvements in and levels compared to olanzapine's average 0.91 kg/month gain. For , two 3-week placebo-controlled trials in 2003-2004 supported ziprasidone's approval for acute . In a study of 139 patients with , ziprasidone monotherapy (mean dose 132 mg/day) resulted in a mean Young Mania Rating Scale (YMRS) total score reduction of -12.4 points versus -7.7 points for (p=0.004), with response rates (≥50% YMRS reduction) of 42.6% versus 20.7%. A second trial with 201 participants showed a -14.3 point drop on ziprasidone compared to -6.9 points on (p<0.001), achieving similar response rates. Long-term efficacy data from a 1-year, double-blind, -controlled (ZEUS study) in 278 stable patients with chronic highlighted ziprasidone's role in prevention. The Kaplan-Meier estimated probability at 1 year was 35-43% across ziprasidone doses (40-160 mg/day) versus 77% for (p<0.001 for all doses), representing a of approximately 40%. All doses also sustained PANSS improvements, particularly in negative symptoms (p<0.05). Meta-analyses from 2010 to 2020 have corroborated these findings, confirming ziprasidone's moderate efficacy in with standardized mean differences (SMD) of 0.4-0.6 versus for overall symptom reduction on PANSS scales. Earlier reviews similarly reported effect sizes in this range, emphasizing consistent benefits over without superiority to other atypicals. Despite these positives, limitations include high dropout rates in certain trials, such as intramuscular ziprasidone studies for acute agitation where approximately 20% of participants discontinued due to adverse events or inefficacy in short-term (24-hour) assessments. This underscores challenges in tolerability for acute settings.

Emerging Applications and Future Directions

Clinical research on ziprasidone's adjunctive role in treatment-resistant depression includes a completed phase II trial (NCT00633399, 2008) examining its addition to selective serotonin reuptake inhibitors (SSRIs), which showed mixed results on improvements in depressive symptoms among non-responders. Similarly, studies have assessed ziprasidone for irritability associated with autism spectrum disorder, based on data indicating reduced maladaptive behaviors in youth. Exploratory studies suggest potential benefits of ziprasidone as an augmenting agent in obsessive-compulsive disorder (OCD) and . In OCD, open-label augmentation with ziprasidone to has demonstrated moderate reductions in compulsive symptoms. For PTSD, small trials indicate possible alleviation of anxiety-like behaviors and core symptoms, though efficacy remains inconsistent. These findings highlight 20-30% symptom improvements in select cohorts, warranting larger randomized controlled trials. Key research gaps persist, particularly regarding ziprasidone's long-term cognitive effects in chronic , where evidence shows modest improvements in domains like and executive function but lacks data on sustained impacts beyond one year. Comparative effectiveness analyses against newer antipsychotics, such as , reveal ziprasidone's favorable metabolic profile but inferior efficacy in global symptom reduction for bipolar , underscoring the need for head-to-head studies in diverse populations. Future directions emphasize development to predict prolongation, a known with ziprasidone; genetic studies have identified variants influencing susceptibility, enabling personalized monitoring. However, challenges include shifting funding toward novel antipsychotics with multimodal mechanisms, potentially limiting ziprasidone's advancement; post-2023 European Union Clinical Trials Register data on adjunctive use in depression reflect mixed outcomes, with variable response rates complicating investment. As of November 2025, no new indications have been approved, and interest in ziprasidone appears limited compared to newer agents.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK448157/
  2. https://www.nature.com/articles/1395273
  3. https://pubmed.ncbi.nlm.nih.gov/12177583/
  4. https://psychiatryonline.org/doi/full/10.1176/appi.ajp.160.4.741
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4843798/
  6. https://www.aafp.org/pubs/afp/issues/2021/0101/p16.html
  7. https://pubmed.ncbi.nlm.nih.gov/26091194/
  8. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020825s065%2C020919s053lbl.pdf
  9. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020825s065,020919s053lbl.pdf
  10. https://www.ncbi.nlm.nih.gov/books/NBK583029/
  11. https://cdn-uat.mdedge.com/files/s3fs-public/Document/September-2017/051_0913CP_SavvyPsych_FINAL.pdf
  12. https://www.nejm.org/doi/full/10.1056/NEJMoa051688
  13. https://psychiatryonline.org/doi/10.1176/appi.ajp.161.9.1709
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC8266572/
  15. https://doi.org/10.1176/appi.ajp.163.3.546
  16. https://doi.org/10.1007/s00787-012-0239-z
  17. https://academic.oup.com/ijnp/article/25/9/737/6572171
  18. https://australianprescriber.tg.org.au/articles/stopping-and-switching-antipsychotic-drugs.html
  19. https://psychopharmacologyinstitute.com/section/antipsychotic-withdrawal-syndrome-symptoms-risks-and-prevention-strategies-2809-5726/
  20. https://labeling.pfizer.com/showlabeling.aspx?id=584
  21. https://medlineplus.gov/druginfo/meds/a699062.html
  22. https://www.tandfonline.com/doi/full/10.1080/15563650701665142
  23. https://mdpoison.com/media/SOP/mdpoisoncom/ToxTidbits/2010/April%202010%20toxtidbits.pdf
  24. https://pubmed.ncbi.nlm.nih.gov/16232029/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC5481298/
  26. https://www.ncbi.nlm.nih.gov/books/NBK459388/
  27. https://www.clintox.org/wp-content/uploads/2016/05/Atipsychotic-Medication-Poisoning.pdf
  28. https://pubmed.ncbi.nlm.nih.gov/28135844/
  29. https://pdf.hres.ca/dpd_pm/00053524.PDF
  30. https://psychopharmacologyinstitute.com/publication/mechanism-of-action-and-pharmacodynamics-of-ziprasidone-2165/
  31. https://go.drugbank.com/drugs/DB00246
  32. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/020825s009lbl.pdf
  33. https://psychiatryonline.org/doi/full/10.1176/appi.ajp.161.5.818
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC3679209/
  35. https://annals-general-psychiatry.biomedcentral.com/articles/10.1186/1744-859X-12-1
  36. https://pubmed.ncbi.nlm.nih.gov/16231965/
  37. https://pubmed.ncbi.nlm.nih.gov/12826984/
  38. https://pubmed.ncbi.nlm.nih.gov/10771458/
  39. https://www.goodrx.com/ziprasidone/interactions
  40. https://pubmed.ncbi.nlm.nih.gov/18007569/
  41. https://www.medcentral.com/drugs/monograph/20568-301013/ziprasidone-oral
  42. https://crediblemeds.org/
  43. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021483s003lbl.pdf
  44. https://pubchem.ncbi.nlm.nih.gov/compound/Ziprasidone
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508293/
  46. https://pubmed.ncbi.nlm.nih.gov/22477804/
  47. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020825s035%2C020919s023lbl.pdf
  48. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20919lbl.pdf
  49. https://www.fda.gov/media/73047/download
  50. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/077561s000ltr.pdf
  51. https://www.drugpatentwatch.com/p/tradename/GEODON
  52. https://assets.hpra.ie/products/Human/13306/LicenseSPC_PA0019-052-006_20012016123125.pdf
  53. https://ptfarm.pl/pub/File/Acta_Poloniae/2012/5/809.pdf
  54. https://www.researchgate.net/publication/225500272_A_Rapid_Stability-Indicating_LC_Method_for_Ziprasidone_Hydrochloride
  55. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c75971f8-9640-a6e8-e053-2995a90af654
  56. https://patents.google.com/patent/US4831031A/en
  57. https://www.nature.com/articles/nrd1523
  58. https://pubmed.ncbi.nlm.nih.gov/7562537/
  59. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-825_Geodan_biopharmr_P1.pdf
  60. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021483s000_ChemR.pdf
  61. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-825_geodan.cfm
  62. https://psychiatryonline.org/doi/10.1176/pn.36.5.0033
  63. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1755-5949.2008.00056.x
  64. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_fda_approval_for_geodon_ziprasidone_hci_capsules_for_the_adjunctive_maintenance_treatment_of_bipolar_disorder_in_adults
  65. https://pharmatimes.com/news/pfizers_zeldox_gets_eu_ok_for_acute_mania_997661/
  66. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020825s015%2C017%2C020919s005%2C006lbl.pdf
  67. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020825s063lbl.pdf
  68. https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-launches-generic-version-of-pfizers-geodon-capsules-in-us-market/articleshow/12122333.cms
  69. https://www.drugs.com/availability/generic-geodon.html
  70. https://www.drugs.com/ingredient/ziprasidone.html
  71. https://www.medindia.net/drug-price/ziprasidone.htm
  72. https://www.healthdirect.gov.au/medicines/brand/amt%2C1303501000168108/ziprasidone-gh
  73. https://www.mayoclinic.org/drugs-supplements/ziprasidone-oral-route/description/drg-20067144
  74. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/077562s000TAltr.pdf
  75. https://www.drugs.com/generic-approvals-archive/2012.html
  76. https://www.goodrx.com/ziprasidone/what-is
  77. https://patents.google.com/patent/EP0965343B1/en
  78. https://www.healio.com/clinical-guidance/drugs/ziprasidone
  79. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3e54e15-945c-4e1e-b992-d01e6872d606
  80. https://www.justice.gov/archive/usao/pae/News/2009/sep/pfizerrelease.pdf
  81. https://www.atg.wa.gov/news/news-releases/pfizer-inc-will-pay-33-million-settle-states-claims-unfair-and-deceptive
  82. https://psychiatryonline.org/doi/full/10.1176/pn.45.12.psychnews_45_12_025
  83. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020825s054%252C020919s041%252C021483s014lbl.pdf
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC556368/
  85. https://www.medpagetoday.com/neurology/alzheimersdisease/870
  86. https://www.nejm.org/doi/full/10.1056/NEJMoa052827
  87. https://www.nolo.com/legal-encyclopedia/risperdal-seroquel-symbyax-zyprexa-antipsychotics-29866.html
  88. https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-Registry-Measures/2017_Measure_383_Registry.pdf
  89. https://pubmed.ncbi.nlm.nih.gov/12668364/
  90. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60733-3/fulltext
  91. https://pubmed.ncbi.nlm.nih.gov/11401000/
  92. https://clinicaltrials.gov/study/NCT00633399
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC5248507/
  94. https://www.researchgate.net/publication/6960826_Ziprasidone_as_coadjuvant_treatment_in_resistant_obsessive-compulsive_disorder_treatment
  95. https://www.sciencedirect.com/science/article/abs/pii/S016643281300051X
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC5935838/
  97. https://pubmed.ncbi.nlm.nih.gov/18670244/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC8112003/
  99. https://www.mdpi.com/1422-0067/23/24/15786
  100. https://www.clinicaltrialsregister.eu/ctr-search/search?query=Ziprasidone
Add your contribution
Related Hubs
User Avatar
No comments yet.